Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol-Reference-Cited by-同舟云学术

Delta and kappa opioid receptor polymorphisms influence the effects of naltrexone on subjective responses to alcohol

Published:2012-12 Issue:2 Volume:103 Page:253-259
ISSN:0091-3057
Container-title:Pharmacology Biochemistry and Behavior
language:en
Short-container-title:Pharmacology Biochemistry and Behavior

Author:

Ashenhurst James R.,Bujarski Spencer,Ray Lara A.

Funder

National Institute on Alcoholism and Alcohol Abuse

General Clinical Research Center Program of the National Center for Research Resources, National Institutes of Health

Publisher

Elsevier BV

Subject

Behavioral Neuroscience,Biological Psychiatry,Clinical Biochemistry,Pharmacology,Toxicology,Biochemistry

Reference66 articles.

1. A review of research on the Alcohol Use Disorders Identification Test (AUDIT);Allen;Alcohol Clin Exp Res,1997

2. Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans;Ananthan;J Med Chem,1999

3. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial;Anton;Am J Psychiatry,1999

4. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking;Anton;Psychopharmacology (Berl),2004

5. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial;Anton;JAMA,2006

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detecting the OPRK1 rs963549 and rs997917 Polymorphisms by Novel PCR-RFLP Methods and Determining Their Genotype/Allele Frequencies in a Turkish Population;Biology Bulletin;2023-08-10

2. Effect of PDYN and OPRK1 polymorphisms on the risk of alcohol use disorder and the intensity of depressive symptoms;Alcohol and Alcoholism;2023-05-12

3. Association of OPRK1 rs963549 and rs997917 polymorphisms with opioid use disorder and related phenotypes;Pharmacogenomics;2023-04

4. Single-dose intravenous ketamine or intramuscular naltrexone for high-utilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates;Addiction Science & Clinical Practice;2022-11-22

5. Alcohol Use Disorder: Neurobiology and Therapeutics;Biomedicines;2022-05-21